Research programme: stem cell-based therapeutics - Pluristem Therapeutics

Drug Profile

Research programme: stem cell-based therapeutics - Pluristem Therapeutics

Alternative Names: Placenta expanded mesenchymal cells; Placental-derived mesenchymal stem cells; PLX-BMP; PLX-BMT; PLX-I; PLX-IBD; PLX-MS; PLX-ORTHO; PLX-PAH; PLX-STROKE

Latest Information Update: 15 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pluristem Life Systems
  • Developer Berlin-Brandenburg Center for Regenerative Therapies; Hebrew University of Jerusalem; New York University School of Medicine; Pluristem Therapeutics; Texas A&M University; United Therapeutics Corporation
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements; Cytokine stimulants; Dopaminergic cell replacements; Stem cell stimulants; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Heart failure; Multiple sclerosis; Musculoskeletal disorders; Myocardial infarction; Parkinson's disease; Preeclampsia; Pulmonary arterial hypertension; Pulmonary fibrosis; Stroke
  • No development reported Diabetic foot; Haematological malignancies; Inflammatory bowel diseases; Neuropathic pain; Pain

Most Recent Events

  • 13 Sep 2017 Pluristem Therapeutics has patent protection for placental expanded (PLX) cells for the treatment of Critical limb ischaemia and muscle regeneration in Hong Kong
  • 07 Nov 2016 Pluristem Therapeutics receives patent allowance for adherent cells from adipose or placental tissues and their therapeutics use in China
  • 11 Oct 2015 Pluristem and Charite of Berlin expand research agreement to include orthopaedic indications
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top